TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Confidence in communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in use of quality indicators
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adequacy of knowledge and skills in working with alcohol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-esteem in working with alcohol
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 3-year survival of implants
Endpoint domain: Mortality/survival
Primary endpoint: Background fluoride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oppositional-defiant disorder (ODD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-hr pad test correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean YMRS total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CGI total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cholesterol increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sitting balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful induction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Active labor following a single dose of gel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Need for Syntocinon augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Marginal Bone Level (MBL) after 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total sleep time with EtCO2 > 50 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphocyte proliferation induced by PHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TWBC count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Normalization of vaginal epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of symptoms of vaginal atrophy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confirmation or exclusion of a probable arrhythmic cause
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tolerability of thioridazine
Endpoint domain: Adverse events/effects
Primary endpoint: ATP depletion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain interference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BRS modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: goal performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: proprioception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bimanual hand use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of breast lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse of P. vivax parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overall success rate of autotransplanted teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 75% improvement in the Psoriasis Area and Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% improvement in the Psoriasis Area and Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's Global Assessment rating of Minimal or Clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reintervention rate for band retrieval or repositioning
Endpoint domain: Adverse events/effects
Primary endpoint: Slippage rate
Endpoint domain: Adverse events/effects
Primary endpoint: nonrelapse mortality (NRM)
Endpoint domain: Mortality/survival
Primary endpoint: Clerkship performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of NSAID induced GU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Risk of DU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: aqueous tear volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: half-life of nuclear material on the ocular surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of nuclear material retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of PAS-R
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Giardia prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hamstring muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quadriceps muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: FMD improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: c-PWV improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: hs-CRP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: survival associated with number of resected nodes
Endpoint domain: Mortality/survival
Primary endpoint: Pregnancy and normal deliveries
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Efficacy of imipramine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wellbeing scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: self-care self-efficacy scores
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: antiviral activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Increases in liver transaminase above the upper limit of normal (ULN)
Endpoint domain: Adverse events/effects
Primary endpoint: Study discontinuation due to adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of perioperatory complications
Endpoint domain: Adverse events/effects
Primary endpoint: Increase of intraocular pressure
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of omeprazole prescribed among PPIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of COX‐2 inhibitors among NSAIDs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative drug costs at 18 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: abnormal white matter volume (AWMV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: readmission rates
Endpoint domain: Mortality/survival
Primary endpoint: Serum vancomycin within the required range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery without removing the central venous catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-hospital death rate
Endpoint domain: Mortality/survival
Primary endpoint: eight year actuarial survival without recurrent myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: takeover quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alertness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: cardiovascular risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: daytime diastolic blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Activation of early maladaptive schemas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to scheduled phone calls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lasting remission without co-medication at week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diastolic blood pressure at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: better outcomes than usual care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival benefit from erlotinib
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness of self-administered rehabilitation program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phagocytosis and oxidative burst of granulocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pro-inflammatory cytokine release in response to LPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mini-Mental State Examination (MMSE) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Alzheimer's Disease Assessment Scale--Cognition scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 30-min urinary excretion of salbutamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24-h urinary excretion of salbutamol and its metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chlamydia test uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Lower pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced need for analgesic medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of days requiring analgesic medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: recurrence of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin response to iron therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Iron tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lower per participant costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in CDS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DOSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VDS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DPQ category scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epworth Sleepiness Scale score improvement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: termination period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uterine rupture
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of overall grade 3-4 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Patient and physician global assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference scores in recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in risk of new vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in risk of incident clinical fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of patency of the infarct-related artery at 90 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Th1 cell percentage increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CTL cell percentage increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-HBs growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: increase in plasma aminotransferases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: venous ulcer healing times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Wound healing outcomes
Primary endpoint: Reduction of cardiovascular risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Basal insulin sensitivity (HOMA-%S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Stimulated insulin sensitivity (M/I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: HbA(1c) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: global cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal mesh erosion rate
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective cure of bulge symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-of-life measurements
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain during strenuous jaw movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical Rating Scale (NRS) scores during chewing and yawning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional wall motion abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure episodes of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in mortality in the active screening arm
Endpoint domain: Mortality/survival
Primary endpoint: Blood glucose concentration postexercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with substantial relief of IBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in sensation to pinprick, touch, and cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: calm scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Infant fussiness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of coital episodes protected by spermicide use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F-specific plasma IgG response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma IgA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: memory B cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom from MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Colour differences of peri-implant soft tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tocilizumab absolute PK bioavailability (AUC∞ ratio (s.c./i.v.))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tocilizumab PD bioavailability for soluble IL-6R (AUClast ratio (s.c./i.v.))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tocilizumab PD bioavailability for C-reactive protein (CRP effect)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery from DSM-IV diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anastomosis identification rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity in detecting polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total NPI scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: arterial-venous oxygen difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brain tissue oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of trimethylamine oxidised to trimethylamine N-oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Health Composite score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: lung cancer-specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: lung cancer cases diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Surgical site wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients requiring relaparotomy
Endpoint domain: Mortality/survival
Primary endpoint: Induction of spherical aberration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and high-order aberration (HOA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast sensitivity values in photopic condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bifidobacteria counts in feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: severity of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: duration of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Mean improvement in PTSD severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Filling of artificial resorptive area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recurrence rate of bacterial vaginosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of remaining cured
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of secondary vaginal candidiasis
Endpoint domain: Adverse events/effects
Primary endpoint: combined risk of fatal and nonfatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative success rates of prostheses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to protein eating patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: shoulder abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: upper limb circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sagittal range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lateral range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of resiliency
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Erythrocyte incorporation of iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vocabulary skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of health clinic visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Circulating levels of AcSDKP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolactin plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: past-year drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the burden of common mental health problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection of low-grade vs high-grade prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: intimate partner violence exposure
Endpoint domain: Adverse events/effects
Primary endpoint: SsVEP contrast thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: side effects rate
Endpoint domain: Adverse events/effects
Primary endpoint: Kansas City Cardiomyopathy Questionnaire summary score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Movement Disorder Society Unified Parkinson Disease Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of subjects with HIV‐1 RNA <50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median CD4+ T‐cell count increases from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes